Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels.

Abstract:

:The potential advantage of using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) methodology to detect metastasis in sentinel lymph nodes (SLNs) of breast cancer (BC) patients was evaluated in this prospective study. We measured the expression of relevant gene transcripts in SLNs using an innovative algorithm and compared the results of single-marker assays versus multi-marker assays with conventional histological detection methods. SLNs from women aged ≥ 18 years diagnosed with unilateral BC were examined by haematoxylin-eosin staining and immunohistochemistry and analysed for transcripts of several relevant genes using qRT-PCR (learning group). Four candidate panels of expressed transcript combinations with high sensitivity and specificity were selected for further investigation. The candidate panels were then validated using SLNs from a second group of BC patients (validation group). In the learning group, 74/314 SLN sections from 150 patients were positive for metastasis by histology. The transcripts analysed showed the following individual sensitivities/specificities: cytokeratin 19 (CK19) 94.6%/97.9%; mammaglobin 1 (MGB1) 82.4%/91.7%; mammaglobin 2 (MGB2) 82.4%/96.7%; carcinoembryonic antigen (CEA) 71.6%/97.5%; EPCAM (epithelial cell adhesion molecule) 91.9%/97.1%; and NY-BR-1 82.4%/93.8%. The optimal panel based on the predefined criteria comprised four markers: CK19, MGB1, EPCAM, and NY-BR-1, of which ≥ 2 had to be positive (95.9% sensitivity, 95.0% specificity, 85.5% positive predictive value (PPV), and 98.7% negative predictive value (NPV)). Overall concordance with histology was 95.2%. In the validation group, 84/315 SLN sections from 235 patients were histologically positive, and panel sensitivity, specificity and overall accuracy were 88.1, 95.2 and 93.3%, respectively, at the SLN section level. In conclusion, molecular staging using expression patterns of relevant transcripts in SLNs could serve as a useful complement to standard diagnostic work-up in BC patients. The proposed flexible multi-parametric approach does not improve the overall accuracy compared with the single-marker approach. However, it overcomes several limitations of the previously reported molecular assays for SLN diagnosis.

authors

Wallwiener CW,Wallwiener M,Kurth RR,Röhm C,Neubauer H,Banys MJ,Staebler A,Schönfisch B,Meuer SC,Giese T,Fehm TN

doi

10.1007/s10549-011-1710-0

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

833-44

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

130

pub_type

杂志文章
  • Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study.

    abstract::The protective effect of vegetables on the risk of breast cancer recurrence is uncertain. We sought to evaluate the association between breast cancer recurrence and vegetable intake including analyses stratified on tamoxifen use. Experimental evidence of anti-carcinogenic activity of phytochemicals in cruciferous vege...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1014-9

    authors: Thomson CA,Rock CL,Thompson PA,Caan BJ,Cussler E,Flatt SW,Pierce JP

    更新日期:2011-01-01 00:00:00

  • The declining use of axillary dissection in patients with early stage breast cancer.

    abstract:OBJECTIVES:To determine any changes in usage of axillary dissection over time from 1983 to 1993, and to characterize those patients who do not receive axillary node dissection. METHODS:A total of 129,946 female patients receiving cancer-directed surgery for early stage breast cancer, who were identified from the SEER ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006170811237

    authors: Du X,Freeman JL,Goodwin JS

    更新日期:1999-01-01 00:00:00

  • Vascular proliferation is a prognostic factor in breast cancer.

    abstract::Angiogenesis is important for the growth and spread of malignant tumors, and anti-angiogenesis treatment is currently being evaluated for breast cancer and other tumors. Although microvessel density is the most commonly used tissue-based marker of tumor associated angiogenesis, it has significant limitations and has n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1785-7

    authors: Arnes JB,Stefansson IM,Straume O,Baak JP,Lønning PE,Foulkes WD,Akslen LA

    更新日期:2012-06-01 00:00:00

  • Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.

    abstract::The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-008-0242-8

    authors: Györffy B,Schäfer R

    更新日期:2009-12-01 00:00:00

  • Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

    abstract::Cytoplasmic HuR is associated with reduced survival in invasive breast cancer. We designed this study to determine the predictive and prognostic value of HuR expression in women with breast cancer who underwent neoadjuvant chemotherapy followed by surgical resection. We immunohistochemically analyzed cytoplasmic HuR e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2679-7

    authors: Wang J,Li D,Wang B,Wu Y

    更新日期:2013-09-01 00:00:00

  • Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

    abstract::The NSABP B-30 trial addresses whether amenorrhea after adjuvant chemotherapy increases survival. Preliminary to the trial outcome analysis, we examined the incidence of amenorrhea and its relationship to symptoms and quality of life (QOL) in the standard-care arm of this adjuvant breast cancer trial. Premenopausal wo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-008-9937-0

    authors: Swain SM,Land SR,Ritter MW,Costantino JP,Cecchini RS,Mamounas EP,Wolmark N,Ganz PA

    更新日期:2009-01-01 00:00:00

  • Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

    abstract::The ErbB2 receptor is a proto-oncogene associated with a poor prognosis in breast cancer. Herceptin, the only humanized anti-ErbB2 antibody currently in clinical use, has proven to be an essential tool in the immunotherapy of breast carcinoma, but induces cardiotoxicity. ErbB2 is involved in the growth and survival pa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2103-8

    authors: Fedele C,Riccio G,Malara AE,D'Alessio G,De Lorenzo C

    更新日期:2012-07-01 00:00:00

  • Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.

    abstract:PURPOSE:Evaluation of the safety and efficacy of a combination of docetaxel and doxorubicin in breast cancer patients. Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of defin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9889-9

    authors: Mukai H,Watanabe T,Ando M,Shimizu C,Katsumata N

    更新日期:2009-01-01 00:00:00

  • Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls.

    abstract::Little is known about quality-of-life (QOL) differences over time between incident ductal carcinoma in situ (DCIS) and early-stage invasive breast cancer (EIBC) cases as compared with same-aged women without breast cancer (controls). We prospectively recruited and interviewed 1,096 women [16.8% DCIS, 33.3% EIBC (25.7%...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2048-y

    authors: Jeffe DB,Pérez M,Liu Y,Collins KK,Aft RL,Schootman M

    更新日期:2012-07-01 00:00:00

  • Age-of-onset heterogeneity in hereditary breast cancer: minimal clues for diagnosis.

    abstract::Knowledge of the family history of cancer may significantly influence diagnosis and surgical management. Hereditary breast cancer (HBC) is common and accounts for approximately 9% of the total breast cancer burden. The pattern of HBC's natural history, including age of onset, increased incidence of bilaterality, integ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01811240

    authors: Lynch HT,Conway T,Fitzgibbons R Jr,Schreiman J,Watson P,Marcus J,Fitzsimmons ML,Lynch JF

    更新日期:1988-12-01 00:00:00

  • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

    abstract::Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-012-2003-y

    authors: Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

    更新日期:2012-06-01 00:00:00

  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

    abstract:PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05454-y

    authors: Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

    更新日期:2020-01-01 00:00:00

  • Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.

    abstract::While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint. However, there are no known published reports about the value of PFS from the patient's perspective. We developed a questionnai...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2734-4

    authors: Hurvitz SA,Lalla D,Crosby RD,Mathias SD

    更新日期:2013-12-01 00:00:00

  • Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.

    abstract::Proteins can be efficiently introduced into cells when fused to a protein transduction domain, such as Tat from the human immunodeficiency virus. We recently reported that dendritic cells transduced with a Tat fusion protein containing the extracellular domain of Her2/neu (Tat-Her2/neu) induced CD8 cytotoxic T lymphoc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-0450-4

    authors: Viehl CT,Tanaka Y,Chen T,Frey DM,Tran A,Fleming TP,Eberlein TJ,Goedegebuure PS

    更新日期:2005-06-01 00:00:00

  • Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

    abstract::The mitochondrial DNA (mtDNA) 4977-bp deletion (DeltamtDNA(4977) mutation) is one of the most frequently observed mtDNA mutations in human tissues and may play a role in carcinogenesis. Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9613-9

    authors: Ye C,Shu XO,Wen W,Pierce L,Courtney R,Gao YT,Zheng W,Cai Q

    更新日期:2008-04-01 00:00:00

  • Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer.

    abstract:PURPOSE:To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician. PATIENTS AND METHODS:Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized pha...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1006483214678

    authors: Okamura H,Yamamoto N,Watanabe T,Katsumata N,Takashima S,Adachi I,Kugaya A,Akechi T,Uchitomi Y

    更新日期:2000-05-01 00:00:00

  • Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.

    abstract::Aberrant expressions of the neuronal protein synuclein gamma (SNCG) in malignant mammary epithelial cells are strongly associated with the progression of breast cancer. SNCG is not expressed in normal breast tissues but abundantly expressed in a high percentage of invasive and metastatic breast carcinomas. Several stu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-6938-0

    authors: Inaba S,Li C,Shi YE,Song DQ,Jiang JD,Liu J

    更新日期:2005-11-01 00:00:00

  • Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.

    abstract:OBJECTIVES:Improvements in the life expectancy of women with breast cancer raise important questions how to improve quality of life (QoL) for women sustaining complications and side effects of cancer treatment. The presented study examined the prevalence of arm morbidity in a cohort of primary breast cancer patients ov...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9247-3

    authors: Albert US,Koller M,Kopp I,Lorenz W,Schulz KD,Wagner U

    更新日期:2006-12-01 00:00:00

  • Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients.

    abstract::The present study consists of 1,238 women with unilateral breast cancer treated with modified radical mastectomy living in the geographic area of Haukeland Hospital. Their weight and height had been measured years before presentation of the disease. Age-adjusted Quetelet's index (weight/height2) showed that obese wome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807157

    authors: Maehle BO,Tretli S

    更新日期:1996-01-01 00:00:00

  • Diagnostic work-up of contralateral breast cancers has not improved over calendar period.

    abstract::Women who have been treated for breast cancer are typically followed up with regular mammography and palpation, with the aim of detecting recurrences and contralateral breast cancer (CBC). This study aims to investigate if the diagnostic work-up of breast cancer patients has improved over the last 25 years and resulte...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0748-8

    authors: Sandberg ME,Hartman M,Edgren G,Eloranta S,Ploner A,Hall P,Czene K

    更新日期:2010-08-01 00:00:00

  • Cultured cell lines from human breast cancer biopsies and xenografts.

    abstract::Eighty-five breast cancer specimens were processed as part of a program in tumor acquisition, propagation, and preservation for biotherapy. Nine long-term culture cell lines were developed. Four cell lines were from solid tumor metastases, two lines were from pleural fluid specimens, and three were from xenograft tumo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806292

    authors: Lewko WM,Vaghmar R,Hubbard D,Moore M,He YJ,Chang L,Husseini S,Wallwork K,Thurman GB,Oldham RK

    更新日期:1990-12-01 00:00:00

  • Flexible covariate effects in the proportional hazards model.

    abstract::The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01840837

    authors: Hastie T,Sleeper L,Tibshirani R

    更新日期:1992-01-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract:PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-018-4770-6

    authors: O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期:2018-08-01 00:00:00

  • Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

    abstract::Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women in...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-009-0309-1

    authors: Henry NL,Rae JM,Li L,Azzouz F,Skaar TC,Desta Z,Sikora MJ,Philips S,Nguyen AT,Storniolo AM,Hayes DF,Flockhart DA,Stearns V,Consortium on Breast Cancer Pharmacogenomics Investigators.

    更新日期:2009-10-01 00:00:00

  • Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.

    abstract::The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0328-y

    authors: Ramón y Cajal T,Altés A,Paré L,del Rio E,Alonso C,Barnadas A,Baiget M

    更新日期:2010-01-01 00:00:00

  • Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

    abstract::Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents in untreated patients. Eribulin (E) has shown activity in patients who have undergone previous taxane, anthracy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-015-3466-4

    authors: Abraham J,Robidoux A,Tan AR,Limentani S,Sturtz K,Shalaby I,Alcorn H,Buyse ME,Wolmark N,Jacobs SA

    更新日期:2015-07-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract::Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-4321-9

    authors: Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期:2005-09-01 00:00:00

  • Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women.

    abstract:INTRODUCTION:The incidence of breast cancer varies among women living in the Southwestern part of the US. We evaluate how body size influences breast cancer risk among these women. METHODS:Cases (n = 2,325) diagnosed with breast cancer between October 1, 1999 and May 2004 residing in Arizona, Colorado, New Mexico, or ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9292-y

    authors: Slattery ML,Sweeney C,Edwards S,Herrick J,Baumgartner K,Wolff R,Murtaugh M,Baumgartner R,Giuliano A,Byers T

    更新日期:2007-03-01 00:00:00

  • Factors predicting in-breast tumor recurrence after breast-conserving surgery.

    abstract:PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0187-y

    authors: Mechera R,Viehl CT,Oertli D

    更新日期:2009-07-01 00:00:00

  • Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

    abstract::Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3677-3

    authors: Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

    更新日期:2016-01-01 00:00:00